TO THE EDITOR
The management of locally advanced rectal cancer has been transformed by neoadjuvant chemoradiotherapy, which achieves substantial primary tumor downstaging and, in a subset of patients, sterilizes regional lymph node metastases. While tumor regression grade (TRG) is an established component of post-treatment pathological evaluation, its prognostic utility is largely restricted to patients without residual nodal disease (ypN0). The complementary challenge, characterizing the spectrum of treatment response within lymph nodes that harbor residual tumor (ypN+), has remained a significant gap in risk stratification. The article by Shi et al[1], published in the World Journal of Gastroenterology, directly confronts this gap and therefore merits detailed critical appraisal.
The central methodological strength of the Shi et al’s study[1] is its rigorous demonstration, via multivariate Cox proportional hazards modeling, that the proposed six-tier lymph node regression grade (LRG) system provides prognostic information independent of established clinical and pathological covariates. This approach reliably establishes LRG as an independent prognostic factor and confirms its independent prognostic value for overall survival. Critically, the authors move beyond a simple validation to examine the dose-response relationship between individual LRG grades and survival outcomes, demonstrating that the biological spectrum of nodal response, not merely its presence or absence, carries prognostic weight. The complementary prognostic roles of TRG and LRG reported in the study are conceptually elegant: TRG stratifies outcomes in ypN0 patients, while LRG provides discrimination specifically in the ypN+ subgroup. This division of prognostic labor suggests that a combined TRG-LRG assessment could achieve comprehensive response evaluation across the entire spectrum of post-neoadjuvant patients.
However, several methodological considerations temper the immediate clinical applicability of these findings. The most significant limitation, which the authors themselves identify, is the histopathological distinction between LRG0 (no evidence of tumor or regressive changes) and LRG1 (pathological complete response with fibrosis). Post-treatment fibrosis can completely efface a prior micrometastatic focus, rendering an LRG1 node morphologically indistinguishable from a never-involved LRG0 node on routine hematoxylin and eosin staining. This diagnostic ambiguity introduces a potential for systematic misclassification that is particularly acute in patients with low-volume metastatic disease, where a complete response is biologically more plausible. The authors do not report inter-observer agreement statistics for the six-tier grading system, yet reproducibility is a prerequisite for clinical adoption; a comparison with simplified two- or three-tier classifications would have illuminated whether the granularity of the six-tier system justifies its inherent variability. Furthermore, the generalizability of the findings may be constrained by the single-center design, as institutional variability in neoadjuvant regimens, pathological processing protocols, and surgical techniques could influence the observed distribution of LRG scores. Independent external validation in multi-institutional cohorts with standardized assessment protocols is therefore essential before LRG can be considered for routine clinical use.
A critical aspect of Shi et al’s methodology that warrants further investigation is the potential to resolve the LRG0/LRG1 conundrum through the integration of ancillary techniques. We propose that cytokeratin immunohistochemistry applied to fibrotic nodal remnants could systematically identify occult carcinoma cells, providing an objective molecular threshold for distinguishing a sterilized metastasis from a true negative node. This limitation is not only pertinent to the study by Shi et al[1] but also represents a common challenge encountered in the assessment of lymph node pathological response following neoadjuvant therapy in other gastrointestinal malignancies.
Beyond morphological assessment, the molecular determinants of lymph node regression remain largely unexplored, yet they hold the key to personalizing neoadjuvant strategies. Several of the genetic pathways classically implicated in colorectal cancer (CRC) progression also represent candidate modulators of treatment response. Inactivation of the APC gene and consequent dysregulation of the Wnt/β-catenin pathway is the initiating event in colorectal carcinogenesis[2], and experimental evidence suggests that Wnt pathway activity modulates chemosensitivity in rectal cancer models[3]. Similarly, the mismatch repair (MMR) status is not merely prognostic but predictive: Tumors with defective MMR exhibit distinct patterns of response to neoadjuvant therapy compared with microsatellite-stable tumors[4]. Whether MSI status correlates with the degree of lymph node regression, and specifically with the likelihood of achieving LRG1, is a clinically relevant question that the Shi et al[1] dataset, if annotated with MMR status, could begin to address. The integration of these molecular features into predictive models could, in the future, identify patients most likely to achieve nodal complete response and thus candidates for non-operative management, vs those destined for a poor nodal response who may benefit from treatment intensification[5].
Epigenetic modifications further expand the repertoire of candidate biomarkers for nodal response prediction. DNA methylation patterns, histone modifications, and non-coding RNA expression are integral regulators of gene expression in CRC and are increasingly recognized as mediators of chemoresistance[6]. Specific methylation signatures have been associated with response to neoadjuvant chemoradiotherapy in rectal cancer, and it is plausible that the epigenetic landscape of lymph node metastases influences their capacity to undergo treatment-induced fibrosis. The metabolic reprogramming characteristic of CRC, encompassing altered glucose, lipid, and amino acid metabolism, may similarly condition the nodal microenvironment and determine whether tumor cells are eradicated or persist as residual deposits[7]. These are not independent phenomena; epigenetic alterations and metabolic shifts are interconnected and jointly regulated by the tumor microenvironment, including the local inflammatory milieu within metastatic lymph nodes.
A particularly under-explored dimension of lymph node regression is the role of oxidative stress in shaping the post-treatment nodal landscape. Reactive oxygen species are a double-edged sword in cancer biology: They potentiate DNA damage and genomic instability that drive carcinogenesis, yet they are also the effector molecules through which ionizing radiation and certain chemotherapeutics induce tumor cell death[8-10]. Within this framework, malondialdehyde (MDA), the most extensively characterized product of lipid peroxidation, emerges as a candidate biomarker of interest. MDA forms covalent adducts with proteins and nucleic acids, alters cellular structural integrity, and has been implicated in the depth of tumor invasion and metastatic progression in CRC[11,12]. We propose that MDA and related oxidative stress markers could serve a dual role in the context of LRG: First, as surrogate indicators of the oxidative damage inflicted by neoadjuvant therapy on nodal metastases, and second, as discriminators between fibrotic LRG1 nodes (where oxidative damage has culminated in tumor sterilization) and native LRG0 nodes (where such damage was never generated). While Shi et al[1] did not explore this avenue, future studies that correlate tissue MDA levels or systemic oxidative stress markers with LRG scores could provide biochemical evidence to resolve the LRG0/LRG1 diagnostic dilemma. Furthermore, the inflammatory milieu fostered by chronic oxidative stress, mediated through Nrf2 and NF-κB signaling, influences both tumor cell survival and the remodeling of the lymphatic microenvironment, thereby potentially modulating the capacity of residual nodal tumor cells to repopulate and drive recurrence[13,14]. The net effect of reactive oxygen species on nodal response is therefore context-dependent and merits systematic investigation as a modifier of LRG-defined prognosis[15,16].
From a clinical decision-making perspective, the value of LRG lies in its potential to guide postoperative management. Currently, adjuvant chemotherapy decisions in locally advanced rectal cancer rely heavily on the binary distinction between ypN0 and ypN+ status. The LRG system introduces a gradient within the ypN+ group that could inform a more nuanced therapeutic approach. Patients with extensive nodal regression (low LRG) may harbor disease that is fundamentally chemosensitive and could potentially be spared the toxicity of intensified adjuvant regimens. Conversely, those with minimal regression (high LRG) likely harbor chemoresistant clones and may be candidates for treatment escalation, inclusion in clinical trials of novel adjuvant strategies, or intensified surveillance protocols that incorporate circulating tumor DNA (ctDNA) monitoring. The integration of LRG into postoperative risk stratification would benefit from direct comparison with emerging liquid biopsy approaches; it is conceivable that the combination of LRG status and postoperative ctDNA detection provides superior prognostic discrimination to either modality alone, and this hypothesis warrants prospective testing.
The role of the gut microbiota in shaping local and systemic immune responses to neoadjuvant therapy is another variable that may influence nodal regression. Specific bacterial species, including Fusobacterium nucleatum and enterotoxigenic Bacteroides fragilis, have been implicated in CRC progression and chemoresistance[17,18]. Whether the composition of the intratumoral or nodal microbiome influences the degree of lymph node regression is an intriguing but entirely unexplored question that could open new avenues for therapeutic modulation of treatment response.
Conclusion
In conclusion, the study by Shi et al[1] provides a valuable conceptual framework that advances the pathological assessment of treatment response beyond the primary tumor into the metastatic nodal compartment. The six-tier LRG system demonstrates that regression is a continuous biological variable with prognostic implications. However, its transition from a research observation to a clinically actionable biomarker requires addressing several priorities. First, external validation in multi-institutional cohorts with standardized grading criteria and formal assessment of inter-observer reproducibility is essential. Second, the integration of cytokeratin immunohistochemistry into the diagnostic algorithm should be prospectively evaluated as a means of resolving the LRG0/LRG1 ambiguity. Third, the correlation of LRG with molecular markers of chemoresistance, including MMR status, epigenetic signatures, and oxidative stress biomarkers such as MDA, may refine prognostic precision and illuminate the biological mechanisms governing nodal response. Fourth, comparative studies that position LRG alongside established and emerging prognostic tools, including TRG and ctDNA, will define its incremental clinical value. Finally, interventional trials that stratify adjuvant therapy decisions based on LRG status are the ultimate test of its utility in personalizing rectal cancer care. We commend Shi et al[1] for opening this important avenue of investigation and encourage the research community to address these unresolved questions in a systematic and collaborative manner.